NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term pipeline growth.

Novartis has reached an agreement to buy a PI3K-targeting drug for breast cancer from Synnovation Therapeutics, paying a ...

EMA’s panel backs a targeted therapy, which reduces lymphadenopathy and restores B-cell populations in patients with activated phosphoinositide 3-kinase delta syndrome.

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer ; The lead ...

Celcuity's gedatolisib, a pan-PI3K/mTOR inhibitor for advanced breast cancer, shows strong early efficacy and is in pivotal Phase 3 trials, yet remains undervalued. The company has a healthy cash ...

Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The current PI3K 3C inhibitors in use in ...

HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...

Efficacy of up-front hematopoietic cell transplantation in peripheral t-cell lymphoma, not otherwise specified (PTCL-NOS): A National Cancer Database analysis. This is an ASCO Meeting Abstract from ...